---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056669"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:40:28.030126+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q1 net loss widens to $19.8M; positive Phase 1a data for ATI-052

## Summary
- Net loss $19.8M vs $15.1M YoY; revenue $2.0M (+33%) on higher Lilly/Sun Pharma royalties.
- Cash & equivalents $190.8M (up from $151.4M); raised $59.8M via 18.4M share ATM offering in March.
- ATI-052 Phase 1a SAD/MAD showed half-life ~45 days, sustained target engagement up to 20 wks; supports Q3-month dosing.
- Phase 1b POC trials in asthma and atopic dermatitis ongoing; top line results expected H2 2026.
- Completed enrollment in bosakitug Phase 2 AD trial; results expected Q4 2026.

## SEC filing metadata
- accession: 0001104659-26-056669
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/0001104659-26-056669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/acrs-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056669
- JSON: https://secwatch.observer/filing/0001104659-26-056669.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056669.txt

## Source-grounded claims
- claim_id: 003a75826e5f4f17666aa65b746a53b1770358fa
  claim: Aclaris Therapeutics, Inc. reported first quarter of 2026 results: revenue $2.0 million, net income Net loss was $19.8 million.
  evidence_excerpt: First quarter 2026 Net loss was $19.8 million for the first quarter of 2026 compared to $15.1 million for the first quarter of 2025. Total revenue was $2.0 million for the first quarter of 2026 compared to $1.5 million for the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/0001104659-26-056669-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.